was appointed Director of Rutgers Cancer Institute and Vice Chancellor for Cancer Programs, Rutgers Biomedical and Health Sciences in January 2017. On October 17th, 2024, Dr. Libutti was named the inaugural William N. Hait Director of Rutgers Cancer Institute. In addition to his leadership roles within Rutgers University, Dr. Libutti serves as Senior Vice President of Oncology Services for RWJBarnabas Health. He is also a Distinguished Professor of Surgery at Rutgers Robert Wood Johnson Medical School and an Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences.
After graduating magna cum laude from Harvard College, Dr. Libutti received his medical degree from the College of Physicians and Surgeons of Columbia University. He remained at Presbyterian Hospital in New York where he completed his residency in surgery, followed by a fellowship at the National Cancer Institute (NCI) in surgical oncology. He continued at the NCI where he became a tenured Senior Investigator and Chief of the Tumor Angiogenesis Section in the Surgery Branch. Following his time at the NCI, he served as the Director of the Montefiore Einstein Center for Cancer Care and as an Associate Director of the Albert Einstein Cancer Center for eight years prior to joining Rutgers and RWJBarnabas Health.
Dr. Libutti is an internationally known expert in the management of neuroendocrine tumors, Past President of the American Association of Endocrine Surgeons, and a member of American Surgical Association and the Association of American Physicians. His clinical practice focuses on gastrointestinal malignancies including cancers of the liver and pancreas. The recipient of funding from the NCI for the past 25 years, Dr. Libutti is also a researcher whose work focuses on developing novel cancer therapies through an understanding of the tumor microenvironment as well as on a better understanding of the tumor suppressor genes MEN1 and FILIP1L. He has published over 325 peer reviewed journal articles, is Editor-in-Chief Emeritus of the Springer-Nature Journal Cancer Gene Therapy and holds eleven U.S. patents. Dr. Libutti has successfully navigated Rutgers Cancer Institute’s P30 CCSG Comprehensive Cancer Center Award through two competitive renewals, the most recent of which in 2023 achieved the Center’s highest score to date placing it among the top centers in the US.
Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with your insurance company they are still a participating plan prior to receiving services or care. Each plan is different and some provide different levels of coverage that could make a difference in your out-of-pocket costs. It is always best for the patient receiving care to contact their insurance company to obtain more information.
Aetna
Amerigroup
Cigna
Consumer Health Plan
Horizon BCBS
Horizon NJ Health
Magnacare
Medicaid
Medicare
Multiplan
Oxford Health
Qualcare HMO
Qualcare PPO
United Community
United Healthcare
United Medicare
WellCare
Articles and Press
Steve K. Libutti, MD, FACS, was awarded a $1.2 million ‘Petersen Accelerator Award’ from the Neuroendocrine Tumor Research Foundation to pursue work leading to precise treatments for neuroendocrine tumors – an uncommon cancer impacting an estimated 171,000 Americans. Learn more
Dr. Steven Libutti Discusses his Research on Neuroendocrine Tumor at Rutgers Cancer Institute
